Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...
Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...
In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...
Amgen shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and rocatinlimab, ...
Zacks.com on MSN1d
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's WhyShares of Amgen AMGN fell by more than 5% on Wednesday after it reported top-line data on two different drugs in the ...
Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...
Bank of America Securities analyst Charlie CY Yang has maintained their neutral stance on AMGN stock, giving a Hold rating today. Charlie CY ...
Wells Fargo analyst Mohit Bansal maintained a Hold rating on Amgen (AMGN – Research Report) yesterday and set a price target of $335.00.
Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the ...
Kyowa Kirin Co., Ltd. (Kyowa Kirin) (TSE:4151) (President and CEO: Masashi Miyamoto) announced top-line results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy ...
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National Medical Products Administration in China has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback